Main Text {#sec1}
=========

Introduction {#sec1.1}
------------

The study of epigenetics and its involvement in metabolic diseases is still a young research field, but it is now attracting a lot of attention and growing at a fast pace. Methodological improvements, with crucial progress each year, have contributed to the current interest and advancements in the field.

Epigenetics has been defined as heritable changes in gene function that take place without a change in the DNA sequence. This classical definition suggests that epigenetics is a heritable trait. However, despite the knowledge that the epigenetic pattern is generally copied through mitotic cell divisions, the heritability through generations is less well established. Epigenetic inheritance through generations as well as the impact of genetic variation on epigenetics are addressed later in this review. Notably, at present, it is common to analyze epigenetic modifications in non-dividing cells, and hence these modifications would not be heritable but may still affect cell-specific gene expression and function. The epigenome includes DNA methylation, histone modifications, and non-coding RNAs, which can regulate cell differentiation, cell-specific gene expression, parental imprinting, X chromosome inactivation, as well as genomic stability and structure. DNA methylation takes place on a cytosine, mainly in CG context or the so-called CpG sites, and to a less extent in non-CG context. Methyltransferases, i.e., DNMT1, DNMT3A, and DNMT3B are responsible for attaching methyl groups to DNA during replication and *de novo* methylation. They use S-adenosyl-L-methionine (SAM) as the methyl donor. There is passive demethylation, e.g., if the activity of DNMTs or the amount of methyl donors is low during replication, and active demethylation, e.g., by ten eleven translocation (TET) enzymes, which may oxidize methyl-groups to hydroxymethylation followed by repair. Moreover, targeted passive demethylation can also occur, when a methylated cytosine is first oxidized to hydroxymethyl-cytosine by TET enzymes, and it stays as such until the next S-phase, when the hydroxymethyl-cytosine is not recognized by DNMT1 and thus becomes an unmethylated cytosine on the newly synthesized strand. Thereby, *cis*-regulatory elements can be targeted by TET enzymes for loss of methylation at specific loci.

Today, researchers have found hundreds of post-translational modifications including acetylation, methylation, phosphorylation, and ubiquitylation on amino terminus or tails of histones. A large number of enzymes are responsible for adding and removing histone modifications, contributing to a complex epigenetic regulation ([@bib62], [@bib127]). Non-coding RNAs have been reviewed elsewhere and will not be covered in the present review ([@bib42], [@bib116]). There is a close relationship between chromatin formation, histone modifications, DNA methylation, and gene activity. In most studies performed in human volunteers it is and will continue to be hard to determine what comes first. Regardless, the information of DNA methylation status will guide us in biology, as it may either influence or indicate gene activity. Differential variability in DNA methylation is commonly seen as a result of epigenetic dysregulation, associated with several phenotypes, pathologies, and an adverse environment. One issue that is important to remember when interpreting the results of DNA methylation is that many of the so-called epigenome-wide association studies are based on an array investigating approximately 450,000 CpG sites, which is about 1.5% of all the CpG sites of the human genome. Keeping that in mind, there is likely many more discoveries to be made now as sequencing-based methods of higher coverage are becoming more available and cost efficient, or in other words, a large proportion of the human epigenome is still a black box, waiting to be discovered. Additionally, as oppose to genetic association studies, epigenetic studies face additional challenges, the most important being the fact that the epigenome is tissue specific, or even cell specific, and that it changes over time.

This review will focus on human studies, which have analyzed DNA methylation in relation to obesity and type 2 diabetes (T2D). However, it will also include some studies that have analyzed histone modifications and the chromatin structure in human tissues of importance for obesity and T2D, as well as some animal studies of interest for this review.

Epigenetics of Obesity {#sec1.2}
----------------------

The prevalence of obesity is increasing at a rate that cannot be explained by genetic factors; rather environmental factors are the likely driver. Considering the rate of the obesity epidemic, it is an appealing thought that our genes are programmed to store fat or to store as much as possible of all the excess energy the body is exposed to. Given the worldwide improvement in living standards, in combination with an abundance of fast food and other high-energy sources, it is hence not difficult to understand the challenge for our bodies to become accustomed to the new environment.

Epigenetics is one of the mechanisms linking environmental factors to altered gene activity and thereby an obvious link between the rapid change in eating habits and the observed obesity phenotypes. As part of the epigenome, DNA methylation may also be a mechanism linking obesity to clinical conditions. Several studies have investigated genome-wide (array-based) DNA methylation and its association with obesity or related phenotypes in human tissues.

Already, in 2013, an epigenetic association study of obesity was published, investigating DNA methylation in peripheral blood leukocytes using the Infinium Human Methylation 450K Beadchip (Illumina, San Diego, CA, USA) ([@bib123]). This study identified several CpG sites associated with obesity in a young cohort ([Table 1](#tbl1){ref-type="table"}) and also showed that the variance of DNA methylation was greater in the obese cases than in the lean controls. This study also indicated that both differential methylation and differential variability could predict obesity with around 70% confidence ([Figure 1](#fig1){ref-type="fig"}). A year later, [@bib37] used the same Illumina 450k array to investigate association with BMI in whole blood, identifying five CpG sites ([Table 1](#tbl1){ref-type="table"}). Among these, three CpG sites are located within *HIF3A*, and the increased methylation with increased BMI was also confirmed in adipose tissue ([Figure 1](#fig1){ref-type="fig"}). *HIF3A* encodes hypoxia-inducible factor 3 subunit alpha, which is part of a group of heterodimeric transcription factors that regulate responses to low oxygen (hypoxia). In another large-scale study investigating DNA methylation in CD4+ T cells, eight CpG sites were associated with BMI and five with waist circumference ([Table 1](#tbl1){ref-type="table"}) ([@bib8]). These included four CpG sites, e.g., annotated to *CPT1A*, *CD38*, and *PHGDH*, which were associated with both phenotypes ([Figure 1](#fig1){ref-type="fig"}). *CPT1A* encodes the enzyme carnitine palmitoyltransferase 1A, which takes part in carnitine-dependent transport across the mitochondrial membrane when oxidation of long-chain fatty acids is initiated and is important for several metabolic processes. DNA methylation in intron 1 of *CPT1A* was inversely associated with both BMI and waist circumference ([@bib8]), a gene for which genetic variation previously has been linked to obesity ([@bib66]). In addition, for *CD38*, the direction of association was confirmed in all three studies and for both phenotypes, here with a positive association, in a CpG site close to the transcription start site ([@bib8]). CD38 also has several links to metabolic traits, e.g., CD38-deficient mice were shown to have a higher metabolic rate and were resistant to obesity induced by a high-fat diet ([@bib10]). In another study, [@bib33] presented numerous CpG sites where DNA methylation in leukocytes associated with BMI or waist circumference ([Table 1](#tbl1){ref-type="table"}). Of these, several were located in genes also found in previous studies of different cohorts or ethnicity, including *HIF3A*, *CPT1A*, and *ABCG1* ([Figure 1](#fig1){ref-type="fig"}). Of interest for obesity, the protein encoded by *ABCG1* is involved in macrophage cholesterol and phospholipids transport. Additionally, 16 CpG sites replicated in adipose tissue, including *CPT1A* ([@bib33]). Another well-powered study of Illumina 450k DNA methylation in whole blood and the association with obesity identified 94 CpG sites associated with BMI and 49 with waist circumference ([@bib103]) ([Table 1](#tbl1){ref-type="table"}). Importantly, they could show that these sites explain 26% and 29%, respectively, of the heritability of these traits. The largest study to date, combining 450k DNA methylation data from over 10,000 whole blood samples, identified 187 CpG sites significantly associated with BMI ([@bib113]) ([Table 1](#tbl1){ref-type="table"}). Using Mendelian randomization, they could show that alterations in DNA methylation in blood are most often the result of obesity but sometimes also the cause, a finding that was also tested and verified in adipose tissue. Importantly, the DNA methylation sites associated with obesity predicted future risk of T2D, which is a major clinical condition associated with obesity ([@bib113]). Mendelian randomization was also used to infer causal relations between BMI and differential methylation and gene expression in whole blood cells ([@bib76]). Again, more CpG sites showed support of being secondary to obesity than the opposite, but this study also provides evidence for DNA methylation sites that contribute to increased BMI. Interestingly, they also showed that 18% of the interindividual variation in BMI could be assigned to the replicated CpGs with differential methylation in blood. Of the 87 CpG sites robustly associated with BMI ([Table 1](#tbl1){ref-type="table"}), gene expression was altered for ten genes, e.g., *ABCG1*, *SREBF1*, and *CPT1A*, and overrepresented in lipid metabolism pathways ([@bib76]) ([Figure 1](#fig1){ref-type="fig"}). *SREBF1* encodes a transcription factor involved in lipid metabolism and may be a target for prevention of coronary artery disease. Adding to the growing numbers of CpG sites significantly associated with BMI and waist circumference ([Table 1](#tbl1){ref-type="table"}), [@bib35] reported novel associations with both phenotypes found in *MS12* and *LARS2* while also confirming previous associations of e.g., *ABCG1*, *SREBF1*, and *CPT1A*. *MSI2*, encoding the Musashi RNA binding protein 2 gene, has a role in post-transcriptional gene regulation and has been associated with eating behavior. Another 29 novel CpG sites associated with obesity were recently described ([Table 1](#tbl1){ref-type="table"}) and also replicated in neutrophils to show that the results from peripheral blood leukocytes are not due to altered cell-type composition ([@bib114]). This study further suggests a direct link between DNA methylation, gene expression, and obesity status for several genes, including *SOCS3* where obesity was associated with decreased methylation and increased gene expression ([@bib114]) ([Figure 1](#fig1){ref-type="fig"}). *SOCS3* expression is upregulated in obesity and has been shown to induce both insulin and leptin resistance, with implications for blood glucose control and energy homeostasis ([@bib90]). The Illumina 450k array has also been used to investigate alterations in DNA methylation associated with childhood obesity ([Table 1](#tbl1){ref-type="table"}) ([@bib44], [@bib56], [@bib99]).Table 1Epigenetic Association Studies of ObesityReferenceSample Size Discovery (*Replication*)PhenotypeTissueIdentified Number of CpG SitesAdditional Information[@bib123]96BMI ≥30 versus BMI \<25peripheral blood leukocytes23,305 ^FDR^age: 14--21 years[@bib37]459BMIwhole blood5 ^FDR^--*339BMI3*^Bonf^*1,789BMI3*^Bonf^[@bib8]991BMICD4+ T cells8 ^Bonf^--waist circumference5 ^Bonf^*1,935BMIwhole blood4*^Bonf^*2,105BMIwhole blood2*^Bonf^*waist circumference3*^Bonf^[@bib33]2,097BMIperipheral blood leukocytes76 ^Bonf^--waist circumference164 ^Bonf^*2,377+991BMIwhole blood/CD4+ T cells37*^Bonf^*991waist circumferenceCD4+ T cells8*^Bonf^[@bib103]641/*2,515*BMIwhole blood/*whole blood*94 ^Bonf^results are based on a meta-analysis of discovery and replication cohortswaist circumference49 ^Bonf^[@bib113]5,387BMIwhole blood278 ^Bonf∗^meta-analysis*4,874BMIwhole blood187*^p\ \<\ 0.05/\*Bonf^[@bib76]3,743BMIwhole blood135 ^Bonf^--*4,055BMIwhole blood/CD4+ T cells83*^Bonf^[@bib35]1,450BMIwhole blood14 ^Bonf^--waist circumference26 ^Bonf^*2,097BMIwhole blood12waist circumference13*[@bib114]700BMI/obese versus leanperipheral blood leukocytes76 ^Bonf^age: 14--36 years*2,097BMIperipheral blood leukocytes54*--*188obese versus leanneutrophils37*[@bib122]510BMIwhole blood20 ^FDR^--[@bib102]96BMI (males)subcutaneous adipose tissue33,058 ^FDR^--94BMI (females)subcutaneous adipose tissue39,533 ^FDR^[@bib16]15before versus after gastric by-pass (women)omental adipose tissue15 ^Bonf^--subcutaneous adipose tissue3,601 ^Bonf^[@bib26]30post-obese versus never obese (women)isolated fat cells8,504 ^FDR_1%^--[@bib44]37obesity (BMI Z score \> 2.5 versus lean controls)whole blood31 ^FDR^age: 3--13 years[@bib99]374BMIwhole blood212 ^FDR^age: 5.5 years[@bib56]149BMIwhole blood129 ^(p\<0.05;\ Δ\>10%)^age: 9--14 years[^1][^2]Figure 1Obesity Is Associated with Differential DNA Methylation and Increased Epigenetic VariabilityThe figure illustrates tissues and genes with observed alterations in DNA methylation due to obesity and related phenotypes (BMI, waist circumference), some of which are also associated with gene expression. Alterations in DNA methylation are more often a result of obesity than the opposite. GBP, gastric by-pass.

With a slightly different perspective, [@bib122] investigated accumulative stress modulation of DNA methylation in whole blood and its effects on obesity. First, DNA methylation of 20 CpG sites was found to be significantly associated with BMI ([Table 1](#tbl1){ref-type="table"}). Among them, interaction between stress and DNA methylation of one CpG site in *SOCS3*, the one that was also identified by [@bib114], was associated with BMI ([Figure 1](#fig1){ref-type="fig"}) ([@bib122]).

Several studies have also investigated the association between DNA methylation and obesity-related traits in adipose tissue, an endocrine organ and the body's main energy reservoir. Using Illuimna's 450k array, [@bib102] identified thousands of CpG sites in subcutaneous adipose tissue (SAT) of 96 males, which were associated with BMI. Interestingly, as many as 2,825 genes were identified where both DNA methylation and gene expression associated with BMI, including *FTO* and *IRS1*. In the female cohort of this study, we could also replicate all three *HIF3A* CpG sites reported by [@bib37]. However, in the male cohort, two other CpG sites of *HIF3A*, also intragenic, were the only ones significantly associated with BMI ([@bib102]) ([Figure 1](#fig1){ref-type="fig"}). Another study identified differential methylation in both omental and SAT in response to gastric by-pass and associated weight loss ([@bib16]) ([Figure 1](#fig1){ref-type="fig"}). One intergenic CpG site overlapped between the tissues, and another two genes showed differential methylation in both tissues (*PDE7B* and *SLC9A3*), however, not for the same CpG loci. In SAT, *KCNQ1* had six significant CpG sites, all with lower DNA methylation after weight loss, and several other genes previously associated with obesity and related traits also displayed altered DNA methylation. In support of this differential methylation observed in SAT, DNA methyl-transferases (*DNMT3A* and *3L*) showed decreased methylation after weight loss, as well as *MBD4*, encoding a protein that binds specifically to methylated cytosines. In addition, three genes encoding histone deacetylases, *HDAC4*, *7*, and *10*, displayed differential methylation in response to gastric by-pass and weight loss ([@bib16]). To follow up on these results, [@bib26] compared DNA methylation in isolated fat cells from women 2 years after gastric by-pass with weight-matched women who had never been obese. Of the 8,504 CpG sites with differential methylation, 27% were linked to adipogenesis, which could be a mechanism for the higher number of fat cells observed in obese and post-obese individuals ([@bib26]). Prospective studies comparing the DNA methylome from various tissues before and after weight loss have shown small but widespread changes across the genome and suggested that baseline DNA methylation can be used as a biomarker for the outcome, i.e., the weight loss response ([@bib7]).

In a recent study by [@bib29], array-based DNA methylation and gene expression were investigated in muscle stem cells from obese and non-obese individuals before and after differentiation. Among obese subjects, methylation of 147,161 CpG sites was significantly altered during differentiation from myoblasts to myotubes, compared to 39,572 sites in non-obese subjects. These abnormal epigenetic changes, found e.g. in *MECP2*, *IL18*, *ENHO*, and *PLCB1* as well as in genes of pathways involved in the immune response, provide one explanation for how obesity may impair myogenesis and thereby affect muscle regeneration and function ([Figure 1](#fig1){ref-type="fig"}).

What we have learned from the observational studies is that obesity and related phenotypes induce epigenetic dysregulation, seen as increased variability in DNA methylation. Obesity is considered a heterogeneous disease, which could influence the outcome, together with different genetic background, gender, and tissue specificity. The latter is an important limitation, as many studies are performed on blood cells, which most likely do not contribute to obesity. To increase the likelihood for obtaining epigenetic results that are biological meaningful, the tissue to study should be carefully selected. Furthermore, when interpreting the published associations between obesity and DNA methylation in blood, it should be kept in mind that some studies include overlapping cohorts to maximize sample size, thereby increasing power. However, DNA methylation data from human adipose tissue, an organ of importance for obesity, supports a role for epigenetics in the disease pathogenesis. Together, these studies support an impact of BMI on epigenetic variation of candidate genes for both obesity and T2D, which seems to affect gene expression and metabolism.

Epigenetics of Type 2 Diabetes in Humans {#sec1.3}
----------------------------------------

Only a decade ago, the first epigenetics studies were performed in pancreatic islets and skeletal muscle from patients with T2D ([@bib11], [@bib70]). Although these initial studies only analyzed DNA methylation of candidate genes or parts of the genome, they identified altered methylation patterns in humans with T2D compared with non-diabetic controls, which clearly supports a role for epigenetics in the growing incidence of diabetes. Since 2008, there have been technical advances and an increasing interest in epigenetics of T2D driving this research field forward.

T2D is characterized by chronically elevated blood glucose levels, which develop due to insulin resistance in combination with impaired insulin secretion. It is well established that aging, a sedentary lifestyle, and obesity contribute to insulin resistance in target tissues including skeletal muscle, liver, and adipose tissue. Pancreatic islet function decreases after long-term exposure to elevated lipid and glucose levels ([@bib50], [@bib49]). Because of aging populations and an increasing prevalence of obesity, the number of patients with T2D is increasing at alarming rates worldwide, and the current prevalence of 422 million people is expected to rise to 592 million in 2035. Of note, 5 million people die from diabetes every year, most often because of cardiovascular events ([@bib24]). Subsequently, there is a huge need to dissect the molecular mechanisms such as epigenetics, which may cause diabetes.

To understand if epigenetics contributes to disease, one must identify epigenetic alterations in diseased versus healthy people. However, once such alterations are identified, it needs to be determined if they cause or if they are secondary to disease. Furthermore, since the epigenetic patterns are cell specific, it is essential to study tissues of importance for a certain disease, e.g., pancreatic islets, skeletal muscle, adipose tissue, and the liver for T2D. Indeed, numerous human epigenetic case-control studies for T2D have been performed in these tissues; some of these results will be summarized here ([Figure 2](#fig2){ref-type="fig"}). These studies have been dependent on technical and bioinformatic advances in tools used to analyze the epigenome.Figure 2Type 2 Diabetes Is Associated with Differential DNA Methylation in Human TissuesThe figure illustrates tissues and genes with observed alterations in DNA methylation in subjects with type 2 diabetes compared with non-diabetic controls. Some of these genes also show differential gene expression and have been shown to functionally affect diabetes-related phenotypes such as insulin secretion. DNA methylation of the genes indicated in blood has been associated with future risk of type 2 diabetes in prospective cohorts.

Initial studies analyzed DNA methylation of candidate genes for T2D such as *INS* (encoding insulin), *PDX1*, *PPARGC1A* (encoding PGC1α), and *GLP1R* (encoding the GLP-1 receptor) in human pancreatic islets from donors with T2D and non-diabetic controls ([@bib48], [@bib70], [@bib124], [@bib125]). Islets from T2D donors were found to have increased DNA methylation and decreased expression of these key genes, which were associated with impaired insulin secretion ([Figure 2](#fig2){ref-type="fig"}). In addition, high glucose and glycated hemoglobin (HbA1c) seemed to directly increase DNA methylation of these genes ([@bib49], [@bib124], [@bib125]).

Development of Illumina's Infinium arrays made it possible to analyze methylation of numerous CpG sites simultaneously. This technology was used to analyze methylation of ∼27,000 and ∼450,000 CpG sites, respectively, in pancreatic islets from T2D and non-diabetic donors ([Table 2](#tbl2){ref-type="table"}) ([@bib31], [@bib119]). [@bib31] found altered DNA methylation of 1,649 CpG sites annotated to 843 genes in islets from 15 T2D cases versus 34 controls. Out of these genes, 102 also exhibited differential gene expression in the islets from T2D donors. *CDKN1A*, *PDE7B*, and *SEPT9* belong to the genes with decreased DNA methylation and increased gene expression in T2D islets ([Figure 2](#fig2){ref-type="fig"}). Functional studies of *CDKN1A* and *PDE7B* demonstrated direct negative effects of promoter methylation on the transcriptional activity of these genes. To mimic the situation of T2D, these three genes were overexpressed in clonal β cells, which resulted in decreased glucose-stimulated insulin secretion. Overexpression of *CDKN1A*, encoding a potent cyclin-dependent kinase inhibitor that regulates cell-cycle progression to G1, also decreased cell proliferation in the clonal β cells ([@bib31]). In diabetic islets, [@bib31] also found differential DNA methylation of CpG sites annotated to several candidate genes for T2D and obesity, as identified by genome-wide association studies (GWASs), such as *ADCY5*, *FTO*, *HHEX*, *IRS1*, *KCNQ1*, *PPARG*, and *TCF7L2* ([Figure 2](#fig2){ref-type="fig"}) ([@bib31]).Table 2Epigenetic Association Studies in Type 2 Diabetes (T2D) Case-Control Cohorts, Based on Illumina's Infinium ArraysReferenceSample SizeTissueIdentified Number of CpG SitesAdditional Information[@bib31]15 cases, 34 controlshuman pancreatic islets1,649 ^FDR\ \<\ 5%,\ Δbeta\>5%^--[@bib119]5 cases, 11 controlshuman pancreatic islets276 ^p\ \<\ 0.01,\ Δbeta\>15%^--[@bib1]96 cases, 96 controlsliver1 ^Bonf^only women[@bib64]8 obese T2D, 7 obese, 7 controlsliver5,834 ^FDR\<25%^three-group comparison; only men[@bib82]14 MZ twin pairssubcutaneous adipose tissue0 ^FDR\<5%^MZ twins discordant for T2D28 cases, 28 controlssubcutaneous adipose tissue15,627 ^FDR\ \<\ 15%^[@bib83]35 cases, 60 controlsliver251 ^FDR\ \<\ 5%^--[@bib96]11 MZ twin pairsskeletal muscle1 ^Perm^MZ twins discordant for T2D5 MZ twin pairssubcutaneous adipose tissue7 ^Perm^[^3]

The Illumina arrays have also been used to analyze DNA methylation in human adipose tissue, liver, and skeletal muscle from subjects with T2D and non-diabetic controls ([Table 2](#tbl2){ref-type="table"}) ([@bib1], [@bib64], [@bib82], [@bib83], [@bib84], [@bib96]). These studies identified numerous CpG sites with altered DNA methylation in target tissues from patients with T2D, supporting the role of epigenetics in the pathogenesis of diabetes ([Figure 2](#fig2){ref-type="fig"}). However, in-line with genetic studies, the effect size of each CpG site was quite modest. This is of no surprise since T2D is a complex, polygenic, and multifactorial disease, and it would be unlikely to find methylation of a few CpG sites that had a large effect size on T2D.

State-of-the-art array-based epigenetic methods used in the described studies only cover a modest part (∼1.5%) of the methylome. To generate a full picture of the epigenome, whole-genome analyses of the spectrum of epigenetic marks are required, e.g., whole-genome bisulfite sequencing (WGBS) for analysis of DNA methylation, chromatin immunoprecipitation followed by sequencing (ChIP-seq) for analysis of histone modifications, and assay for transposase-accessible chromatin using sequencing (ATAC-seq) for analysis of chromatin accessibility. WGBS was used to analyze methylation of ∼2.4 × 10^7^ CpG sites (83% of all CpG sites in the human genome) in islets from T2D subjects and controls ([@bib120]). This analysis identified 25,820 differentially methylated regions (DMRs) in the T2D islets. Interestingly, two of the most significant DMRs covered *PDX1*, a key transcription factor in islets that regulates insulin expression ([Figure 2](#fig2){ref-type="fig"}). Additionally, there was an overlap between T2D candidate genes identified by DIAGRAM ([@bib104]) and the T2D-associated islet DMRs, including 159 DMRs annotated to 43 T2D genes, such as *ADCY5*, *TCF7L2*, and *KCNQ1*. Furthermore, 457 genes, including *NR4A3*, *PARK2*, *PID1*, and *SOCS2*, had both DMRs and expression changes in T2D islets ([Figure 2](#fig2){ref-type="fig"}). When some of these candidate genes were either overexpressed or silenced in cultured β cells to represent the situation in diabetic islets, insulin secretion was impaired, thus connecting epigenetic mechanisms to islet dysfunction ([@bib120]). As expected, islet methylation levels were linked to certain histone marks, and combinations of these different epigenetic marks are likely part of the machinery controlling gene activity and chromatin structure. Moreover, methylated DNA immunoprecipitation (MeDIP)-seq was used to study methylation in blood from monozygotic twin pairs discordant for T2D ([@bib126]). Here, the strongest replicated signal was annotated to *MALT1*, which encodes a protein involved in insulin and glycemic pathways and related to taurocholate levels in blood.

Notably, genome-wide histone modifications have so far only been analyzed in pancreatic islets of non-diabetic subjects ([@bib18], [@bib89], [@bib109]), whereas other studies performed in blood cells have included subjects with T2D ([@bib55], [@bib88]). In addition, histone modifications have been analyzed in monocytes cultured in normal and high glucose ([@bib77]). The same applies for analysis of the chromatin structure, for example by ATAC-seq, where mainly samples from non-diabetic people have been used ([@bib2], [@bib110], [@bib115]). Therefore, there is a large need for further epigenome-wide studies in tissues from subjects with T2D. Some of these studies should be performed in sorted cell fractions and/or using single-cell analyses.

Epigenetic changes in patients with diabetes may eventually contribute to vascular complications. Indeed, there is a growing body of literature linking epigenetic modifications to diabetic complications such as retinopathy, diabetic kidney disease, stroke, and myocardial infarction ([@bib3], [@bib14], [@bib17], [@bib23], [@bib80]).

Together, these pioneering studies have identified epigenetic alterations in tissues from patients with T2D, indeed showing a link between epigenetics and diabetes in humans. Numerous of the epigenetic changes were also associated with differential gene expression. Functional follow-up studies suggest that epigenetics may contribute to phenotypes characterizing diabetes. However, future studies need to test if the identified epigenetic alterations are causative for diabetes and phenotypes related to the disease.

Diet and Epigenetics in Relation to Human Obesity and T2D {#sec1.4}
---------------------------------------------------------

Several lines of evidence indicate that epigenetics have important effects on obesity and T2D in humans. The next question is how do epigenetic alterations arise in obese and diabetic people? To start with, our diet contains methionine and folate, which provide us with methyl donors, e.g., SAM through the methionine cycle ([@bib40], [@bib41]). Ducker and Rabinowitz recently reviewed "One-Carbon Metabolism in Health and Disease," which is why we refer to their work for more details in this field ([@bib40]). DNA and histone methyltransferases (DNMTs and e.g., SET7/9 and KMT2D) can attach methyl groups to our DNA and histone tails. To achieve an optimal gene regulation, this process needs to be balanced throughout the genome and in all human cells. SAM and its product S-adenosylhomocysteine (SAH) levels have been used as indicators of methylation capacity ([@bib21]). However, while plasma levels of methionine, folate, SAM, SAM/SAH ratio, B~12~, and homocysteine have been used as markers of methylation capacity and risk of disease, plasma levels may not reflect their corresponding status within tissues and the cell nucleus ([@bib41]). Unfortunately, it has been difficult to obtain simultaneous plasma and tissue measurements for many of these metabolites over time under various nutrient inputs.

Nevertheless, it has been shown that subjects with T2D have reduced levels of folate in the circulation ([@bib83]). Additionally, these folate levels correlated positively with the average degree of DNA methylation of 236 CpG sites with significantly decreased methylation in liver biopsies from T2D versus control subjects ([@bib83]). Moreover, a higher dietary intake of folate was prospectively associated with a lower risk of diabetes in women ([@bib54]). When a subclinical folate deficiency was created in postmenopausal women, plasma homocysteine increased and lymphocyte DNA methylation decreased ([@bib57]). Evidence from an animal study supports the importance of folate, as folic acid reduced the fat mass and serum glucose levels as well as improved insulin resistance in mice fed a high-fat diet ([@bib69]). Additionally, it altered the DNA methylation pattern of genes associated with obesity and T2D in adipose tissue of these mice. Intake of saturated fatty acids may also affect the epigenome, as it was shown that exposure to high levels of palmitate increased histone acetyl transferase (HAT) activity and altered histone acetylation in clonal β cells ([@bib75]). Indeed, the intracellular metabolism provides us with acetyl groups, which can be attached to or removed from histone tails by HATs or HDACs, respectively, and thereby regulate gene activity ([@bib62]). This fundamental knowledge suggests that the unhealthy diet of many obese and diabetic people may affect their epigenome and thereby disease pathogenesis.

Several intervention studies have been performed to dissect the impact of different diets on the human epigenome. These interventions include high-fat diet overfeeding and fasting studies, as well as a randomized control trial of saturated fatty acids (SFAs) versus polyunsaturated fatty acids (PUFAs) ([@bib19], [@bib47], [@bib52], [@bib58], [@bib59], [@bib92]) ([Figure 3](#fig3){ref-type="fig"}). A 5-day high-fat diet overfeeding, mimicking the diet seen in many obese people, changed both the gene expression and methylation patterns in human skeletal muscle and adipose tissue ([@bib19], [@bib47], [@bib58], [@bib59]). Importantly, it seemed easier to induce methylation changes by overfeeding than to reverse them by a control diet.Figure 3Different Diets and Nutrients Are Associated with Differential DNA Methylation in Human Tissues Including Adipose Tissue, Skeletal Muscle, and Pancreatic IsletsThe figure illustrates tissues and genes with observed alterations in DNA methylation in response to human diet interventions (overfeeding either polyunsaturated fatty acids \[PUFAs\] or saturated fatty acids \[SFAs\] for 7 weeks; 5-day high-fat overfeeding; or 36-h fasting), as well as human pancreatic islets cultured in either 1 M palmitate or 16.7 mM glucose versus control for 48 h. Some of these genes also show differential expression, and the diets and nutrients further affect metabolism and clinical phenotypes.

The interest in fasting and its profound health benefits has increased over recent years ([@bib36]). People born with a low birth weight (LBW) have an increased risk of metabolic diseases, and they respond differently to prolonged fasting than normal birth weight (NBW) people ([@bib60]). Leptin and adiponectin are expressed and secreted from adipocytes. These two adipokines control food intake and insulin sensitivity. Obese and T2D subjects have higher leptin and lower adiponectin levels compared to healthy controls, which contribute to dysregulation of their satiety and insulin resistance. [@bib52] recently studied the effects of 36-h fasting on DNA methylation and expression of the genes encoding leptin and adiponectin (*LEP* and *ADIPOQ*) in human adipose tissue from healthy young men born with an LBW or NBW. Fasting increased methylation of CpG sites annotated to both *LEP* and *ADIPOQ* in NBW men but had no effect in LBW men ([Figure 3](#fig3){ref-type="fig"}). This may be due to lower epigenetic flexibility in LBW men; they had a higher degree of *LEP* and *ADIPOQ* methylation at baseline compared with NBW men, and their methylation did not increase further in response to fasting. Moreover, serum leptin levels decreased with 36-h fasting in both birth weight groups, while serum adiponectin levels did not change. In contrast, *ADIPOQ* mRNA levels increased in LBW men, whereas *LEP* expression did not change with fasting. It is possible that the timing, 36-h fasting, contributed to the differences seen in expression and secretion of these adipokines.

Not only the amount but also the type of dietary fat has significant effects on metabolic pathways involved in obesity and T2D ([@bib73]). Visceral obesity and ectopic fat accumulation, both risk factors for diabetes and cardiovascular disease, are influenced by the dietary fat composition ([@bib98]). A randomized controlled trial, including a 7-week diet of either excessive SFAs or PUFAs, resulted in similar weight gain between the two groups; however, the diet high in SFAs was associated with elevated liver and visceral fat accumulation compared with PUFA. Notably, in adipose tissue, DNA methylation of 4,875 CpG sites was affected differently between the two diets ([@bib92]) ([Figure 3](#fig3){ref-type="fig"}). In addition, the methylation level in blood samples of preadolescents has been associated with the intake of PUFA or SFA ([@bib117]).

To study the impact of dietary factors on the epigenome of human pancreatic islets, these were exposed to high levels of glucose or palmitate *in vitro* for 48 h ([@bib50], [@bib49]). First, both glucose and palmitate exposure impaired glucose-stimulated insulin secretion. Second, in an attempt to understand the mechanism, it was shown that exposure to high glucose levels altered both methylation and expression of *GLRA1*, *RASD1*, *VAC14*, *SLCO5A1*, and *CHRNA5* ([@bib49]). Remarkably, palmitate had a more pronounced effect on the islets, where 290 genes with differential expression had a corresponding change in DNA methylation, for example, *TCF7L2* and *GLIS3*. Interestingly, out of the genes with altered expression due to palmitate treatment in human islets, 67 were also associated with BMI and 37 were differentially expressed in T2D patients ([@bib50]).

Thus, dietary factors seem to alter the epigenome in several human tissues of importance for metabolism and may thereby affect gene expression and the pathogenesis of obesity and T2D.

Physical Activity and Epigenetics {#sec1.5}
---------------------------------

Lifestyle interventions, including regular exercise, are known to prevent or delay incidence of T2D in individuals with an increased risk for the disease ([@bib65], [@bib112]). Exercise has a beneficial effect not only on glucose homeostasis and whole-body energy balance but also on the immune system. As for other environmental factors, epigenetics is thought to mediate these external stimuli to partly regulate gene expression and phenotypic outcome. In humans, several studies have investigated how exercise, acute or long-term, influences DNA methylation in skeletal muscle and adipose tissue ([@bib12], [@bib43], [@bib84], [@bib101]).

In 2012, Nitert et al. discovered altered DNA methylation of genes in the MAPK, insulin, and calcium signaling pathways in skeletal muscle from men with a family history of T2D ([@bib84]). This study also showed that long-term exercise alters DNA methylation, for example, of genes such as *MEF2A*, *RUNX1*, *NDUFC2*, and *THADA*, important in T2D and muscle physiology. Furthermore, *in vitro* methylation of these promoter regions confirmed their ability to silence gene expression. The same year, Barrès et al. showed that a single bout of exercise decreases promoter DNA methylation of *PPARGC1A*, *PDK4*, and *PPARD* in human skeletal muscle while increasing gene activity of these key substrate metabolism genes ([@bib12]). Also in adipose tissue, the epigenetic signature is altered in response to exercise ([@bib43], [@bib101]). In men with a previous low level of physical activity, a 6-month exercise intervention altered the level of DNA methylation of numerous CpG sites, covering a total of 7,663 genes throughout the genome ([@bib101]). These include candidate genes for obesity and T2D such as *CREB4*, *GRB14*, *TUB*, *FTO*, *ADCY5*, *TCF7L2*, and *KCNQ1*. Importantly, for one-third of the gene regions with absolute methylation changes \>5%, a simultaneous change in mRNA expression was also observed, and these included candidate genes such as *HDAC4* and *NCOR2*, both with an increase in DNA methylation and a corresponding decrease in mRNA expression after exercise. Functional experiments *in vitro* confirmed that these two genes affect lipogenesis in adipocytes, concluding that epigenetics may be a link between exercise and adipocyte metabolism ([@bib101]). In addition, acute exercise points to epigenomic and transcriptomic changes in adipocyte-specific genes ([@bib43]). This study also suggests that the epigenetic response to exercise is more evident in the trained versus untrained state, whereas the transcriptional response to acute exercise is reduced after a period of endurance training.

Of importance for exercise physiology, a candidate gene approach for 5′ adenosine monophosphate-activated protein kinase (AMPK) showed that 4 weeks of extensive exercise induced altered promoter methylation of *PRKAA2*, the catalytic subunit of AMPK, in human blood ([@bib63]). This finding was verified in mice skeletal muscle, where increased DNA methylation was associated with reduced mRNA and protein expression.

It is now evident that both acute and long-term exercise significantly impact DNA methylation in a highly gene- and tissue-specific manner. Future studies should address if epigenetics can explain the individual response to certain exercise and what the mechanisms would be. One hypothesis is that altered baseline DNA methylation would impair the ability to respond to muscle contractions by further altering the methylome, and consequently, the epigenetic regulation of gene expression due to exercise would be diminished. Indeed, one study in human skeletal muscle recently showed associations between exercise response, based on phosphocreatine recovery rate, and altered DNA methylation and expression levels ([@bib108]). The results point to epigenomic and transcriptomic alterations in glutathione and mitochondrial metabolism, as well as in insulin signaling, and some of the epigenetic differences were also observed in myogenic progenitor cells.

Age and Epigenetics {#sec1.6}
-------------------

Aging is associated with increased abdominal obesity, insulin resistance, and T2D. A better understanding of age-related molecular mechanisms that predispose to obesity and T2D may help develop new therapies and prevention strategies. Although DNA methylation is considered a stable epigenetic mark, the epigenome itself is not stable over time. The reprogramming during embryonic development is the most pronounced period, but the epigenetic drift is strongly associated with aging, where the genome gains and loses methylation stochastically over time ([@bib45]). In 2005, Fraga et al. found that the epigenome was similar in cells from young monozygotic twin pairs, whereas it was different in elderly twin pairs, supporting a pronounced effect of age on DNA methylation. Since then, numerous studies have investigated the impact of aging on the epigenome in human tissues of importance for obesity and T2D including adipose tissue, skeletal muscle, the liver, and pancreatic islets ([@bib9], [@bib20], [@bib71], [@bib100], [@bib102]). Interestingly, DNA methylation of 3,470 sites changed significantly with aging in three different cell types i.e., adipose tissue, liver, and blood ([@bib20]), and methylation of some CpG sites seems to be affected in the same way in all studied tissues, e.g., *FHL2*, *ELOVL2*, and *KLF14*. *FHL2* or four and a half LIM domains 2 has been implicated in Wnt signaling and diabetic kidney disease ([@bib68]). *ELOVL2* encodes an ELOVL fatty acid elongase, which seems to regulate lipid metabolism in β cells by channeling palmitate toward β-oxidation instead of ceramide synthesis ([@bib15]). Additionally, *KLF14* encodes a transcription factor, and single nucleotide polymorphisms (SNPs) associated with *KLF14* expression increase the risk of T2D and affect high-density lipoprotein (HDL) cholesterol levels ([@bib107]). Moreover, obesity was found to influence age-driven epigenetic changes, which provides a molecular link between aging and obesity ([@bib6]). How these age-related epigenetic changes take place remains to be elucidated. For example, what makes a certain methyl transferase change DNA methylation with age at a certain CpG site in several different tissues?

Interaction between Genetics and Epigenetics in Relation to Obesity and Diabetes {#sec1.7}
--------------------------------------------------------------------------------

As DNA methylation mainly occurs on the nucleotide cytosine (C) when followed by a guanine (G), it is obvious that genetic variation that removes or introduces such a CG dinucleotide can and will affect the possibility for DNA methylation in this position. Notable, ∼25% of all SNPs introduce or take away a CpG site. In 2007, we identified an SNP annotated to *NDUFB6*, which introduces a CpG site and thereby affects DNA methylation and gene expression in human skeletal muscle in an age-related manner ([@bib71]). However, apart from this direct effect of genetic variants on DNA methylation, it is less clear if genetic variants also affect DNA methylation more distant, and what would be the mechanism for this. It is also not known to what extent this occurs throughout the genome and how it contributes to clinical phenotypes.

In 2013, we further showed that 48% of the genetic variants associated with T2D, at that point, indeed introduced or removed a CpG site ([@bib32]). As expected, all analyzed CpG-SNPs were associated with DNA methylation, and for 37.5% the SNPs also affected methylation of surrounding CpG sites. This study was performed in human pancreatic islets, and some of the T2D CpG-SNPs were also associated with gene expression, alternative splicing, and insulin secretion ([@bib32]). This study was extended, and in 2014, we presented a genome-wide picture of associations between genetic and epigenetic variation in human pancreatic islets ([@bib85]). Numerous SNP-CpG pairs in *cis* were identified as well as in *trans* (here defined as a distance \>500 kb between the SNP and CpG site); the mechanism for the latter remains to be explained. These associations in *cis* include reported diabetes genes, e.g., *ADCY5*, *KCNJ11*, *HLA-DQA1*, *INS*, *PDX1*, and *GRB10*. We further identified SNP-CpG pairs that associated with gene expression and insulin secretion, and causal inference tests (CIT) pointed to DNA methylation as the potential mediator of genetic association with gene expression and insulin secretion. For example, the CIT identified causal relationships between SNPs, DNA methylation, and expression of genes annotated to the human leukocyte antigen (HLA) region, which are strongly linked to type 1 diabetes. Genes involved in glutathione metabolism, including *GSTT2* and *GSTT1*, were also identified by CIT. This study identified several candidate genes, and the ones that were functionally tested (*GPX7*, *GSTT1*, and *SNX19*) indeed showed effects on key biological processes such as proliferation and apoptosis in pancreatic β cells ([@bib85]). A DNA methylation quantitative trait locus (mQTL) analysis, based on the Illumina 450k array, was also performed in human adipose tissue ([@bib121]). More than 100,000 significant mQTLs were identified, again highlighting the tight connection between genetic variation and DNA methylation. These mQTLs include obesity, lipid, and T2D locus identified by GWASs, e.g., *POMC*, *APOA5*, *CETP*, *FADS2*, *GCKR*, *SORT1*, and *LEPR*. Numerous SNPs in significant mQTLs were also associated with adipose tissue gene expression, BMI, lipid traits, glucose, and insulin levels; phenotypes which may be predisposed to obesity and T2D. Once again, it was shown that genetic variants mediate the effect on metabolic traits including BMI and HbA1c via altered levels of DNA methylation ([@bib121]).

[@bib13] performed an integrative genetic and epigenetic analysis of T2D risk loci, where they identified haplotype-specific methylation in the *FTO* region. After a thorough investigation, the most significant variation of methylation based on genetic background was found in a genomic region of 7.7 kb, harboring a putative enhancer region. Hence, epigenetic analysis may be one way to narrow down the large LD blocks identified in GWASs and to find the functional element connecting genotype to phenotype ([@bib13]). A publication a year later confirmed that *FTO* risk variants alter the epigenome ([@bib5]). Here, another *FTO* risk allele was associated with DNA methylation of five CpG sites, annotated to six different genes. In an attempt to understand how SNPs identified from GWASs act to influence body mass, data for 52 obesity-associated SNPs were connected to Illumina 450k array methylation data in blood from 355 individuals ([@bib118]). This study revealed 28 SNPs that affected a total of 107 CpG sites, of which 35% were located in promoter regions.

The more we learn, the more there is to understand, and for future genomic studies we need to integrate as many aspects of the DNA and chromatin structure as possible. Gene regulation is a highly complex process starting from the nucleotide sequence, adding on DNA methylation, small interfering RNA molecules and histone modifications, with the epigenetic modifications also being affected by both genetic and environmental influences. Importantly, results from CIT suggest that epigenetic mechanisms may cause phenotypes related to diabetes and obesity in humans.

Epigenetic Inheritance Related to Obesity and Diabetes {#sec1.8}
------------------------------------------------------

It is an interesting and challenging hypothesis that epigenetic inheritance contributes to evolution. With the rapid change of our environment during the last decades, changes to our epigenome provide adaptation faster than through genetic mutations, while it is reversible and can be gradually lost. Intergenerational inheritance refers to parental effects where exposures before or during pregnancy may affect the germ cells or the offspring and its reproductive cells. In that way, environmental factors may affect three generations at a time ([Figure 4](#fig4){ref-type="fig"}). Hence, to define true transgenerational epigenetic inheritance, i.e., persistent changes that are not due to the original exposure directly, the phenotype must be observed also in the fourth generation. To our knowledge, there is limited, if any, research providing evidence for transgenerational epigenetic inheritance in humans, and the fact that epigenetic changes are dynamic and transient in nature adds another challenge to this research field. Looking beyond human studies, there are still limited data on true transgenerational epigenetic effects, which requires transmission from F0 to F3 or further, and these have mainly been seen in *C. elegans* ([@bib91]). However, several studies have made attempts to study transfer of epigenetic mechanisms through some generations and link these to obesity and T2D.Figure 4Illustration of How the Environment Affects Three Generations at a TimeAt time of conception, the environment influences the parents, including the spermatozoa methylome and the *in utero* environment and eventually has the possibility to affect both the fetus and its reproductive cells. Evidence for transgenerational epigenetic inheritance in humans, which requires four generations or more, is still sparse.

Epigenetic mechanisms are necessary in the regulation of cell differentiation, but when it comes to reproduction, the epigenetic pattern was originally thought to be completely reset at certain stages of early development. In rodents, it has been clearly demonstrated that the epigenetic states are not entirely reprogrammed ([@bib79], [@bib95]). In comparison to human studies, rodents have a short generation span, and in these studies, the influence of genetic background as well as environmental factors can be controlled. An epigenetic modification at the agouti locus in mice affects gene expression and causes yellow fur, obesity, and diabetes. The epigenetic state of this locus has been shown to be inherited between generations, through the female germline ([@bib79]). There are also examples of paternal transmission of epigenetic information, where offspring to male mice on a high-fat diet display altered metabolic phenotypes, including obesity and β cell dysfunction, and gene expression in the pancreatic islet ([@bib81]).

At present, there are also a number of studies supporting intergenerational epigenetic inheritance in humans. Observations from the Pima Native Americans have shown that offspring from mothers with T2D during pregnancy, as compared to non-diabetic mothers, develop both T2D and obesity at a higher risk (45 versus 1.4% and 58 versus 17%, respectively) ([@bib94], [@bib93]). This effect seems, partly, to be independent of genetics. Importantly, these findings were followed by a study of siblings born before and after their mothers were diagnosed with T2D, limiting the impact of genetic and external environmental factors. Here, the risk of T2D and obesity was significantly higher in the siblings born after the mother developed T2D, strongly suggesting the intrauterine exposure to mediate the risk independent of genetic background ([@bib25]). There is also strong epidemiological data linking prenatal exposure to famine with persistent epigenetic differences, as well as increased risk of disease, later in life ([@bib51], [@bib97]). Early gestation seems to be the most vulnerable period and is associated with obesity among other common diseases, while glucose intolerance was seen in individuals exposed to famine during any time of gestation ([@bib97]). Differential DNA methylation of several genes important for metabolic disease, e.g., *IGF2*, *INSIGF*, and *LEP*, were reported and were, apart from stage of gestation, also dependent on sex of the exposed fetus ([@bib51], [@bib111]). Another study supporting epigenetic inheritance is the Överkalix study, where food supply during the child's slow growth period was linked to common diseases and mortality over three generations ([@bib61]). Here, it was shown that if the paternal grandfather had an abundance of food during this period, diabetes mortality increased.

To understand the link between maternal hyperglycemia and offspring obesity, an epigenetic candidate gene approach was undertaken to investigating DNA methylation levels of *LEP*, a gene regulating energy balance ([@bib4]). Using Mendelian randomization, this study showed that maternal hyperglycemia decreases *LEP* DNA methylation levels in offspring and is associated with higher cord blood leptin levels. This suggests that epigenetic regulation induced by the *in utero* environment may contribute to increased adiposity later in life. Another human study investigated how pre-pregnancy BMI affected the offspring epigenome and adiposity ([@bib105]). Interestingly, methylation of a number of CpG sites (n = 28) were significantly altered in cord blood from offspring of obese mothers but many more (n = 1,621) when the mother was underweight. Paternal BMI seemed to be of less importance according to the results from this study, as did gestational weight gain ([@bib105]). Taking this approach forward to a large, well-powered replicated study, [@bib106] presented robust associations between maternal BMI and DNA methylation of 86 sites in blood from newborns. Of these, the signal was persistent in adolescents for 72 sites; however, causal inference was only observed for 8 of the sites. In another study, [@bib53] found differential DNA methylation of 76 sites in the blood of 93 offspring to women with gestational diabetes mellitus (GDM) compared with 95 controls. While most of these methylation differences were because of confounding by maternal pre-pregnancy BMI, methylation changes of 13 sites were independently associated with maternal GDM.

As evidence for paternal transmission of epigenetic information is emerging, it seems like the developing embryo is controlled not only by maternal influences. The spermatozoa, similar to the somatic cells, has an epigenome that is dynamic and influenced by environmental factors, which likely affect the phenotype of the next generation ([@bib38]). For example, DNA methylation and the expression of sncRNAs is altered in spermatozoa from obese men, and interestingly, the sperm DNA methylome is remodeled after bariatric surgery ([@bib39]). This study points to genes known from genetic association studies of obesity, including *FTO*, *MC4R*, *BDNF*, and *CHST8*. Also, exercise has the ability to reprogram the sperm methylome in humans ([@bib34]), whether these changes are inherited and beneficial for the offspring remains to be established.

How Can Epigenetics Contribute to How We Practice Medicine in the Future? {#sec1.9}
-------------------------------------------------------------------------

As described in this review, epigenetic modifications in key tissues seem to contribute to development of obesity and T2D ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). It is hence possible that current knowledge in epigenetics could be translated into the clinic to prevent further increase in disease prevalence and to develop new therapies. Regular exercise and healthy diets are known to prevent the development of T2D in individuals at risk for disease ([@bib65], [@bib112]). However, identification of subjects with a high risk of developing T2D and obesity is a criterion for disease prevention. Epigenetic biomarkers may be used for the prediction of obesity and T2D in future medicine. These biomarkers should be developed in easily accessible human cells such as blood ([@bib46]). Such epigenetic biomarkers are already in clinical use for prediction in cancer patients ([@bib87]). Moreover, several studies have analyzed DNA methylation in the blood of prospective cohorts for T2D ([@bib9], [@bib22], [@bib30], [@bib113]). Interestingly, methylation of the *ABCG1* locus was associated with an increased risk, whereas methylation of *PHOSPHO1* was associated with a decreased risk for future T2D in several studies ([@bib22], [@bib30]) ([Figure 2](#fig2){ref-type="fig"}). Moreover, the *ABCG1* site showed increased methylation in both adipose tissue and blood from the diabetic twins in monozygotic twin pairs discordant for T2D, while methylation of *PHOSPHO1* was decreased in skeletal muscle of diabetic versus control twins ([@bib30]). A different study showed that blood-based epigenetic biomarkers reflect age-associated DNA methylation changes in human pancreatic islets and associate with future insulin secretion and T2D ([@bib9]). Here, aging was found to increase methylation of sites annotated to *KLF14*, *FHL2*, *ZNF518B*, and *FAM123C* in both human pancreatic islets and blood ([Figure 2](#fig2){ref-type="fig"}). Moreover, increased methylation in blood of the same sites was associated with higher insulin secretion and decreased risk of T2D ∼10 years later in prospective cohorts. Perfilyev et al. also found association between DNA methylation in adipose tissue at baseline and weight increase in response to extra energy intake ([@bib92]). Epigenetic biomarkers that translate from target tissue to blood may subsequently be of clinical relevance since they can be readily analyzed in patients and high-risk populations for diabetes. However, new studies identifying epigenetic markers with a better predictive capacity are needed and these should perform better than current factors known to predict diabetes.

The reversible nature of epigenetic modifications, together with recent advances in epigenome-targeting methods, provides us with new opportunities for novel epigenetic therapies ([@bib72]). If one could identify causal epigenetic mechanisms in obesity and T2D, these could be targeted for novel treatments. In a recent study, [@bib86] targeted demethylation at the *CDKN1C* locus, a cell-cycle regulator, to repress p57 expression and induce β-cell replication. Together these studies support future epigenetic editing attempts in obesity and T2D treatment.

Several pharmacological agents already exist with effects on DNA methylation and histone modifications, including DNMT inhibitors (e.g., Aza) and histone deacetylase inhibitors (HDACi, e.g., VPA and TSA). Moreover, epigenetic drugs have been tested with good results, e.g., for leukemia where Aza is first-line treatment for higher-risk myelodysplastic syndromes, and BET and IDH1/2 inhibitors, which are in clinical trials to treat acute myeloid leukemia (AML). Epigenetic drugs may also affect key tissues for obesity and T2D. Notably, there is a growing body of literature showing that HDACs regulate glucose homeostasis and islet function ([@bib67], [@bib74], [@bib78], [@bib101]). An HDACi, MC1568, was recently found to improve insulin secretion in pancreatic islets from human donors with T2D ([@bib28]). MC1568 inhibits HDAC7, which has increased expression and decreased DNA methylation in pancreatic islets from diabetic versus non-diabetic donors ([@bib27]). Overexpression of HDAC7 in clonal β cells and rat islets resulted in impaired glucose-stimulated insulin secretion and mitochondrial dysfunction. However, the chronic nature of T2D implies lifelong use of drugs, and it is important to carefully weigh the benefits against the risks. Low specificity and global action of HDACi may lead to side effects. Therefore, development of selective epigenetic drugs may represent an avenue for future therapeutic purposes.

Discussion and Conclusions {#sec1.10}
--------------------------

Almost all the knowledge we have concerning epigenetic dysregulation in relation to human obesity and T2D has emerged during the last 10 years. With that in mind, the advancements are tremendous, and for future perspectives, the research field holds unlimited possibilities. Larger cohorts are needed, suggestively through worldwide collaborations, and because of the tissue- or even cell-specific nature of epigenetic information, more human biopsies are desirable. Several studies report small, but significant, changes on a group level, whereas a paired study design is harder to find. As metabolic diseases are heterogeneous in nature, the interindividual variation is large, and several small changes may act together to influence the phenotype. The use of single-cell types would allow to better connect the epigenome to the transcriptome and to define the extent of alterations needed in DNA methylation to affect gene expression. Moreover, mQTL studies and CITs have linked SNPs via significant differences in DNA methylation to differential gene expression in human tissues.

It is an exciting observation that many of the regions that display altered DNA methylation in response to environmental influences or in certain pathologies, are often seen in more than one tissue and are observed under several medical conditions. This suggests that some regions of our DNA and chromatin is less stable, hence more vulnerable to external stimuli, which results in epigenetic dysregulation or variability. Thereby, collaborations across research fields could further improve our understanding of the human epigenome and also guide in method development. Within the near future, genome-wide sequencing is needed to fully dissect the DNA methylome in combination with other epigenetic modifications; however, in the long run, the aim should be to dissect regions with large epigenetic variability and with shown function in gene expression and phenotype transmission. Thus, targeted methods may be developed that maximize the epigenetic information obtained, in spite of reduced coverage, cost, and statistical penalties.

There is now enough evidence to establish that the human epigenome contributes to diseases and also interacts with and responds to various physiological conditions ([Figure 5](#fig5){ref-type="fig"}). Aging and genetic variation are both important contributors to the epigenetic variability seen in individuals affected by obesity or T2D. Furthermore, the *in utero* environment and external factors such as physical activity and availability of nutrients affect the epigenome. Most important, the transient and reversible nature of epigenetic modifications provides an open field for discovery of targets for future prediction and therapeutic concepts in obesity and T2D.Figure 5Interactions between the Environment, the Epigenome, and Obesity and Type 2 DiabetesSeveral genetic and non-genetic factors contribute to the development of obesity and type 2 diabetes. The same factors, e.g., exercise, genetic predisposition, diet, intrauterine environment, and aging, are also known to influence the human epigenome. Furthermore, the epigenome may both contribute to disease and interact with and respond to various physiological conditions of heterogeneous diseases.
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[^1]: All studies are based on the Illumina 450k array. Results from replication(s) within the studies (where applicable) are marked in italic.

[^2]: FDR, false discovery rate \< 0.05; Bonf, Bonferroni correction for multiple testing; FDR_1%, FDR \< 0.01.

[^3]: FDR, false discovery rate; Bonf, Bonferroni correction for multiple testing; Perm, Permutation correction; MZ, monozygotic.
